-+ 0.00%
-+ 0.00%
-+ 0.00%

Entera Announces Second Quarter 2026 Financial Results and Business Updates

Barchart·08/07/2026 15:05:00
Listen to the news

U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.